DEVELOPMENT OF TRANSITION-STATE MIMETIC HIV PROTEASE INHIBITORS

一些可能有用的后天获得性脑损伤治疗方法 免疫缺陷综合征(AIDS)及其相关疾病相继出现。 2‘，3’-双脱氧核苷酸家族的用途，例如 3‘-叠氮-2’，3‘-二脱氧胸苷(AZT或齐多夫定)，2’，3‘双脱氧胞苷 (DDC或扎西他滨)和2‘，3’-二脱氧肌苷(ddi或didanosine)，其 靶向人类免疫缺陷病毒I型逆转录酶 艾滋病的病原体(HIV-1)就是这样一种方法。艾滋病毒也 编码一种病毒特异性天冬氨酸蛋白酶，该酶对其 复制。HIV蛋白水解酶介导关键的蛋白质降解过程 病毒复制后期的病毒蛋白前体。 因此，HIV蛋白水解酶也代表了病毒的特异性靶点 艾滋病毒感染的治疗。

A number of potentially useful approaches for the therapy of acquired immunodeficiency syndrome (AIDS) and its related diseases have emerged. The use of family of 2',3'-dideoxynucleotides, such as 3'-azido-2',3'-dideoxythymidine (AZT or zidovudine), 2',3'dideoxycytidine (ddC or zalcitabine), and 2',3'-dideoxyinosine (ddI or didanosine), which target the reverse transcriptase of human immunodeficiency virus type I (HIV-1), the causative agent of AIDS, is one such approach. HIV also codes a virus-specific aspartic protease which is essential for its replication. The HIV protease mediates crucial proteolytic processing of viral protein precursors at a late stage in the replication of the virus. Thus, HIV protease also represents a virus-specific target for the therapy of HIV infections.